Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 – 18, 2022, in Milan, Italy.
Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex. The presentation will be available for viewing on-demand by registered participants.
Mr. Dyer and Dr. Lütjens will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact IR@addexpharma.com.
